Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent O…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.